Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Reproterol

Generic name
Reproterol
Brand name
ATC Code
R03CC14

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Asthmatic status
  • Intravenous
    • 3 months up to 18 years
      • Initial dose: 1 microg./kg/minute in 10 minutes. or alternatively 1,2 microg/kg/dose as a bolus injection.
      • Maintenance dose: titrate maintenance dose dependent on effect and under control of heart rate (max. 200/min) in steps of 0,1 microg/kg/min every 10-30 min up to 0.2 - 2 microg./kg/minute, continuous infusion.
      • Duration of treatment:

        36-48 hours

      • Phase-out over 6-24 hours.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Selective beta-2-adrenoreceptor agonists
R03CC02

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. MEDA Pharma GmbH & Co. KG, SmPC Bronchospasmin® 1 ml Injektionslösung (82718.00.00), 09/2020
  2. MEDA Pharma GmbH & Co. KG, SmPC Bronchospasmin® 10 ml Injektionslösung (82719.00.00), 08/2020

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes